Revvity, Inc. announced the launch of its Signals Research Suite, a unified, cloud-native SaaS platform that drives scientific collaboration across R&D disciplines from drug discovery to specialty chemicals material development.
The new solution from Revvity Signals Software, the software and informatics arm of Revvity, is available worldwide. It integrates the Revvity Signals Notebook, VitroVivo and Inventa applications into a single, robust solution that supports the entire drug development process, from early research and in vitro testing and safety to early development as well as specialty chemicals new product development.
The Signals Research Suite includes a trio of scientifically intelligent and integrated software applications that serve the entire Make-Test-Decide lifecycle. It features advanced analytics, visualizations powered by TIBCO Spotfire, native industry gold standard ChemDraw integration, and a modern, streamlined interface that allows for complete control in configuring workflows for a wide-range of technique, modality and datatype interfaces. With secure single-sign-on access to all applications, as well as centrally located data tutorials, training videos and software release information, Signals Research Suite users can spend more time focusing on their experiments instead of switching between independent solutions.
Developed in line with best practices for data security and integrity, the Signals Research Suite implements 24/7 global security monitoring, alerting and escalation by the Revvity Signals Software Security Operations Center. The platform can be deployed in either a multi-tenant or private-cloud environment and is designed to meet standard IT requirements for automatic updates and cloud security controls. Also, by automating routine tasks and workflows, data within the Suite is findable, accessible, interoperable and reproducible (FAIR), aiding in data integrity and regulatory compliance.
